BCM
SAGE

Bridgeway Capital Management’s Sage Therapeutics SAGE Stock Holding History

Bridgeway Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,000
Closed -$866K – 1269
2025
Q2 		$866K Buy
+95,000
New +$699K 0.02% 682

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bridgeway Capital Management's SAGE Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 95,000 shares — an estimated $866K sold.

Bridgeway Capital Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $866K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Bridgeway Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 95,000 Sage Therapeutics shares in Q3 2025, an estimated $866K.
  • Bridgeway Capital Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Bridgeway Capital Management's Sage Therapeutics position peaked at $866K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.